Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia [ Studio sull'efficacia e la sicurezza di tre diversi dosaggi di Lais Ambrosia compresse in pazienti con rinocongiuntivite allergica al polline di Ambrosia]

Next Previous
X
Search
Trial Profile

Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia [ Studio sull'efficacia e la sicurezza di tre diversi dosaggi di Lais Ambrosia compresse in pazienti con rinocongiuntivite allergica al polline di Ambrosia]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ragweed allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Lofarma S.p.A

    • Most Recent Events

    • 05 Oct 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 14 Nov 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top